Asia Pacific Antibodies Contract Manufacturing Market Size & Outlook
Related Markets
Asia Pacific antibodies contract manufacturing market highlights
- The Asia Pacific antibodies contract manufacturing market generated a revenue of USD 3,478.4 million in 2021.
- The market is expected to grow at a CAGR of 13.2% from 2022 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2021.
- Monoclonal Antibodies is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2022 to 2030.
Asia Pacific data book summary
| Market revenue in 2021 | USD 3,478.4 million |
| Market revenue in 2030 | USD 10,591.1 million |
| Growth rate | 13.2% (CAGR from 2021 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Polyclonal Antibodies |
| Key market players worldwide | Lonza Group Ltd, Samsung BioLogics, WuXi Biologics (Cayman) Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Boehringer Ingelheim, AGC Biologics, Shenzhen Hepalink Pharmaceutical Group Co Ltd Class H, Emergent BioSolutions Inc, Thermo Fisher Scientific Inc, Labcorp Drug Development, Catalent Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 29.1% of the global antibodies contract manufacturing market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,591.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibodies Contract Manufacturing Market Scope
Antibodies Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Shenzhen Hepalink Pharmaceutical Group Co Ltd Class H | View profile | 2080 | No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, China, People's Republic of, 518057 | https://www.hepalink.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | https://www.samsungbiologics.com/ |
| AGC Biologics | View profile | 1001-5000 | Bothell, Washington, United States, North America | http://www.agcbio.com/ |
| Labcorp Drug Development | View profile | 10001+ | Princeton, New Jersey, United States, North America | https://drugdevelopment.labcorp.com |
| Emergent BioSolutions Inc | View profile | 1600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | https://www.emergentbiosolutions.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| WuXi Biologics (Cayman) Inc | View profile | 12740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | https://www.wuxibiologics.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| FUJIFILM Holdings Corp | View profile | 83784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | http://www.fujifilmholdings.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Asia Pacific antibodies contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibodies contract manufacturing market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 70.9% in 2024. Horizon Databook has segmented the Asia Pacific antibodies contract manufacturing market based on monoclonal antibodies, polyclonal antibodies covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Antibodies Contract Manufacturing Product Outlook (Revenue, USD Million, 2018-2030)
- Monoclonal Antibodies
- Polyclonal Antibodies
- Others
- Asia Pacific Antibodies Contract Manufacturing Source Outlook (Revenue, USD Million, 2018-2030)
- Mammalian
- Microbial
- Asia Pacific Antibodies Contract Manufacturing End Use Outlook (Revenue, USD Million, 2018-2030)
- Biopharmaceutical Companies
- Research Laboratories
- Others
Reasons to subscribe to Asia Pacific antibodies contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific antibodies contract manufacturing market databook
-
Our clientele includes a mix of antibodies contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific antibodies contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific antibodies contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific antibodies contract manufacturing market size, by country, 2018-2030 (US$M)
Asia Pacific Antibodies Contract Manufacturing Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
